Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 430 East 29th Street, Suite 900 NEW YORK NY 10016 |
Tel: | N/A |
Website: | https://www.intracellulartherapies.com |
IR: | See website |
Key People | ||
Sharon Mates Chairman of the Board, Chief Executive Officer | Michael I. Halstead President | Lawrence J. Hineline Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary |
Suresh K. Durgam Executive Vice President, Chief Medical Officer | Mark Neumann Executive Vice President, Chief Commercial Officer |
Business Overview |
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company's product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity. |
Financial Overview |
For the fiscal year ended 31 December 2023, Intra-Cellular Therapies Inc revenues increased 86% to $464.4M. Net loss decreased 45% to $139.7M. Revenues reflect Grant revenue increase of 86% to $2.2M. Lower net loss reflects Biopharmaceutical segment loss decrease of 40% to $159.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.72 to -$1.46. |
Employees: | 610 as of Feb 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $6,251M as of Dec 31, 2023 |
Annual revenue (TTM): | $464.37M as of Dec 31, 2023 |
EBITDA (TTM): | -$158.85M as of Dec 31, 2023 |
Net annual income (TTM): | -$139.67M as of Dec 31, 2023 |
Free cash flow (TTM): | -$124.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 96,807,191 as of Feb 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |